Current Urology Reports

, Volume 10, Issue 4, pp 254–260 | Cite as

Primary care physician versus urologist: How does their medical management of LUTS associated with BPH differ?

  • Martin M. Miner


Medical and surgical therapies for benign prostatic hyperplasia (BPH) are based largely on the results from adherence to the 2003 American Urological Association Guidelines. However, with the emergence of medical therapies as first-line treatment and the expansion of medical therapy for lower urinary tract symptoms (LUTS) into the primary care office, the evaluation and management of men presenting with urinary symptoms can vary depending on provider type. This review explains the basis for BPH medical management in primary care with the review of three key studies. In addition, this review utilizes the data provided by the first longitudinal, observational BPH registry to evaluate patient outcomes and practice patterns in both urologist and primary care offices. From these data, we can conclude that men seeing urologists were more likely to be on medical therapy than men seeing primary care physicians (PCPs), who more often utilized watchful waiting. Urologists also were more likely to prescribe 5-α-reductase inhibitors (5ARIs), combination therapy with an α-blocker and 5ARI, and anticholinergic therapy. In contrast, the use of nonselective α-blockers was appreciably greater among men seeing PCPs than men seeing urologists.


Benign Prostatic Hyperplasia Lower Urinary Tract Symptom Prostate Volume International Prostate Symptom Score Tamsulosin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Margolis S, Carter HB: Prostate disorders. In The Johns Hopkins White Paper. Baltimore: Johns Hopkins Medicine; 2002.Google Scholar
  2. 2.
    Lepor H: Challenges in the detection and diagnosis of bladder dysfunction: optimal strategies for the primary care physician. Rev Urol 2004, 6(Suppl 1):S1–S2.Google Scholar
  3. 3.
    McConnell JD, Roehrborn CG, Bautista OM, et al.: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387–2398.PubMedCrossRefGoogle Scholar
  4. 4.
    Barkin J, Guimarães M, Jacobi G, et al.: Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5-alpha-reductase inhibitor dutasteride. Eur Urol 2003, 44:461–466.PubMedCrossRefGoogle Scholar
  5. 5.
    Fitzpatrick JM: Should combination therapy be standard for benign prostatic hyperplasia? Nat Clin Pract Urol 2005, 2:574–575.PubMedCrossRefGoogle Scholar
  6. 6.
    Roehrborn CG, Siami P, Barkin J, et al.: The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008, 179:616–621. (Published erratum appears in J Urol 2008, 180: 1191.)PubMedCrossRefGoogle Scholar
  7. 7.
    Steers WD, Nuckolls J, Seftel AD, et al.: Differences between PCPs and urologists in the evaluation of men with LUTS/BPH [abstract 6]. Presented at the American Urological Association 2006 Annual Meeting. Atlanta, Georgia; May 20–25, 2006.Google Scholar
  8. 8.
    Wei JT, Nuckolls J, Miner M, et al.: Differences in medical management of LUTS/BPH between PCPs and urologists [abstract 7]. Presented at the American Urological Association 2006 Annual Meeting. Atlanta, Georgia; May 20–25, 2006.Google Scholar
  9. 9.
    Roehrborn CG, McConnell JD, Lieber M, et al.: Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999, 53:473–480.PubMedCrossRefGoogle Scholar
  10. 10.
    Kuritzky L: A primary care physician’s perspective on benign prostatic hyperplasia. Rev Urol 2003, 5(Suppl 5):S42–S48.PubMedGoogle Scholar
  11. 11.
    Naslund MJ, Costa FJ, Miner MM: Managing enlarged prostate in primary care. Int J Clin Pract 2006, 60:1609–1615.PubMedCrossRefGoogle Scholar
  12. 12.
    Djavan B, Fong YK, Harik M, et al.: Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years. Urology 2004, 64:1144–1148.PubMedCrossRefGoogle Scholar
  13. 13.
    Boyle P, Roehrborn CG, Harkaway R, et al.: 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. Eur Urol 2004, 45:620–627.PubMedCrossRefGoogle Scholar
  14. 14.
    McConnell JD, Bruskewitz R, Walsh P, et al.: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998, 338:557–563.PubMedCrossRefGoogle Scholar
  15. 15.
    Roehrborn CG, Boyle P, Nickel JC, et al.: Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002, 60:431–434.CrossRefGoogle Scholar
  16. 16.
    Roehrborn CG, Marks LS, Fenter T, et al.: Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004, 63:709–715.PubMedCrossRefGoogle Scholar
  17. 17.
    Andriole G, Bruchovsky N, Chung LW, et al.: Dihydrotestosterone and the prostate: the scientific rationale for 5-alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol 2004, 172(4 Pt 1):1399–1403.PubMedCrossRefGoogle Scholar
  18. 18.
    Kaplan SA: Use of alpha-adrenergic inhibitors in treatment of benign prostatic hyperplasia and implications on sexual functioning. Urology 2004, 63:428–434.PubMedCrossRefGoogle Scholar
  19. 19.
    Lepor H: Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 1995, 45:406–413.PubMedCrossRefGoogle Scholar
  20. 20.
    Lepor H: Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998, 51:892–900.PubMedCrossRefGoogle Scholar
  21. 21.
    Narayan P, Tewari A: A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998, 160:1701–1706.PubMedCrossRefGoogle Scholar
  22. 22.
    Roehrborn CG: Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Alfus Study Group. Urology 2001, 58:953–959.PubMedCrossRefGoogle Scholar
  23. 23.
    AUA Practice Guidelines Committee: AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003, 170(2 Pt 1):530–537.Google Scholar
  24. 24.
    Wright EJ, Fang J, Metter EJ, et al.: Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol 2002, 167:2482–2488.CrossRefGoogle Scholar
  25. 25.
    Roehrborn CG: Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia, but not acute urinary retention: results of a 2-year placebocontrolled study. BJU Int 2006, 97:734–741.PubMedCrossRefGoogle Scholar
  26. 26.
    Miner M, Rosenberg MT, Perelman MA: Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006, 28:13–25.PubMedCrossRefGoogle Scholar
  27. 27.
    Rosen R, Altwein J, Boyle P, et al.: Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 2003, 44:637–649.PubMedCrossRefGoogle Scholar
  28. 28.
    Siami P, Roehrborn CG, Barkin J, et al.: Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials 2007, 28:770–779.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Men’s Health Center, Miriam Hospital, Warren Alpert Medical SchoolBrown UniversityProvidenceUSA

Personalised recommendations